Support and Resistance Levels
Past performance
About Sai Life Sciences Ltd Sai Life Sciences Limited, established in 1999, is a contract research, development, and manufacturing organization (CRDMO) that specializes in offering end-to-end services for small molecule drug discovery, development, and manufacturing. The company supports global pharmaceutical innovators and biotechnology firms across the value chain, with expertise in both discovery/contract research and CMC/CDMO capabilities. Over the years, the company has undergone multiple name changes, with its current name restored in 2012, reflecting its commitment to life sciences.
Expanding its global and technological footprint, Sai Life Sciences has achieved significant milestones, including the merger of Prasad Drugs Limited in 2004, acquisition of Merrifield Pharma Private Limited in 2006, and the establishment of advanced facilities for drug discovery and development. Notable initiatives include the launch of Sai Nxt in 2020, aimed at positioning the organization as a new-generation CDMO, and recent facilities in the U.S. at Watertown (Greater Boston) and Cambridge, Massachusetts, which emphasize innovation in small molecule drug development.
The company’s growth continued with the development of state-of-the-art facilities in Hyderabad for discovery biology and chemistry, as well as the 2023 launch of a high-potency API manufacturing block at Bidar, Karnataka. Additionally, in early 2024, Sai Life Sciences expanded its capabilities to include API developability and formulations at its Hyderabad Unit II plant, underscoring its evolving service portfolio.
Sai Life Sciences is now gearing up for its Initial Public Offering (IPO), seeking to raise Rs 800 Crores through a combination of Offer for Sale and Fresh Issue, providing traders with a unique opportunity to invest in a rapidly growing, innovation-driven CRDMO with a strong global presence and robust future outlook.